Total Credits: .75
Recent Advances inManagement of Soft Tissue Sarcoma
Historically there are few systemic treatment options for soft tissue sarcoma. Dr. Yoo will discuss emerging targeted therapies.
Educational Objectives:
Outline histopathology, diagnostic evaluation and prognostic factors of soft tissue sarcoma
Demonstrate management of advanced/metastatic disease
Illustrate highlights in emerging targeted agents and immunotherapy
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Osteopathic Association (AOA). The Arizona Osteopathic Medical Association (AOMA) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians.
GRIEVANCE POLICY: The AOMA strives to provide continuing medical education programs to fulfill the needs of the attendees and to meet the AOA Uniform Guidelines and AOA Accreditation Requirements. Comments, questions, or complaints should be forwarded to AOMA Executive Director Josephine Zammuto, by calling the AOMA Office at 602-266-6699 or by mail to AOMA, 1951 W. Camelback Rd., Suite 105, Phoenix, AZ 85015, or by email to info@azosteo.org.
Robert Yoo, DO is a dual board-certified medical oncologist/hematologist at Ironwood & Cancer Research Centers. He completed hematology/oncology fellowship training at Karmanos Cancer Institute/Wayne State University School of Medicine in Detroit, Michigan as a chief clinical fellow. He earned his D.O. degree at Michigan State University School of Osteopathic Medicine and completed internal medicine residency at William Beaumont Hospital in Detroit, Michigan. He is an active member of AOMA, AOA, American Society of Clinical Oncology, and the American Society of Hematology.
Dr. Yoo has no disclosures
| 5 |
|
| 4 |
|
| 3 |
|
| 2 |
|
| 1 |
|